# Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374

**Authors:** Tjalf Ziemssen, Marie Groth, Veronika Eva Winkelmann, Tobias Bopp

PMC · DOI: 10.3390/vaccines12080911 · Vaccines · 2024-08-12

## Full-text entities

- **Chemicals:** Siponimod (MESH:C578989)
- **Species:** Homo sapiens (human, species) [taxon 9606], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11359778/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11359778/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11359778/full.md

---
Source: https://tomesphere.com/paper/PMC11359778